ID28160A - Sistem pengobatan untuk pemberian fenilasetilglutamina, fenilasetilisoglutamina dan/atau fenilasetat. - Google Patents

Sistem pengobatan untuk pemberian fenilasetilglutamina, fenilasetilisoglutamina dan/atau fenilasetat.

Info

Publication number
ID28160A
ID28160A IDW20010174A ID20010174A ID28160A ID 28160 A ID28160 A ID 28160A ID W20010174 A IDW20010174 A ID W20010174A ID 20010174 A ID20010174 A ID 20010174A ID 28160 A ID28160 A ID 28160A
Authority
ID
Indonesia
Prior art keywords
pharmaceutical composition
phenilasetylisoglutamina
phenilasetylglutamina
phenilasetate
provision
Prior art date
Application number
IDW20010174A
Other languages
English (en)
Indonesian (id)
Inventor
Stanislaw R Burzynski
Original Assignee
Stanislaw R Burzynski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanislaw R Burzynski filed Critical Stanislaw R Burzynski
Publication of ID28160A publication Critical patent/ID28160A/id

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IDW20010174A 1998-07-23 1999-07-02 Sistem pengobatan untuk pemberian fenilasetilglutamina, fenilasetilisoglutamina dan/atau fenilasetat. ID28160A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Publications (1)

Publication Number Publication Date
ID28160A true ID28160A (id) 2001-05-10

Family

ID=22397538

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010174A ID28160A (id) 1998-07-23 1999-07-02 Sistem pengobatan untuk pemberian fenilasetilglutamina, fenilasetilisoglutamina dan/atau fenilasetat.

Country Status (21)

Country Link
US (2) US6258849B1 (ru)
EP (1) EP1098643B1 (ru)
JP (2) JP2002521329A (ru)
KR (4) KR100417100B1 (ru)
CN (3) CN1605334A (ru)
AT (1) ATE257378T1 (ru)
AU (1) AU759278B2 (ru)
BR (1) BR9912356A (ru)
CA (1) CA2336945C (ru)
DE (1) DE69914084T2 (ru)
DK (1) DK1098643T3 (ru)
EA (1) EA004179B1 (ru)
ES (1) ES2214866T3 (ru)
HK (1) HK1037142A1 (ru)
ID (1) ID28160A (ru)
IL (1) IL140848A (ru)
NZ (1) NZ509244A (ru)
PL (1) PL213698B1 (ru)
PT (1) PT1098643E (ru)
WO (1) WO2000004894A2 (ru)
ZA (1) ZA200100622B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
DE60140491D1 (de) 2000-08-29 2009-12-24 Biocon Ltd Verwendung einer pharmazeutischen Zusammensetzung mit einem Para-Aminophenylessigsäurederivat für die Behandlung von entzündlichen Erkrankungen des Magen-Darmtrakts
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
AU2005274165A1 (en) * 2004-07-28 2006-02-23 Board Of Regents, The University Of Texas System 3-halo-2-oxopropionate salts and esters as novel anticancer agents
PL2153870T3 (pl) 2004-11-26 2014-05-30 Ucl Business Plc Kompozycje zawierające ornitynę oraz fenylooctan lub fenylomaślan do leczenia encefalopatii wątrobowej
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
JP6144488B2 (ja) 2009-04-03 2017-06-07 オセラ セラピューティクス, インコーポレイテッド L−オルニチンフェニルアセテートおよびその製造方法
SG176675A1 (en) 2009-06-08 2012-01-30 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
CN103502203B (zh) 2010-10-06 2016-09-07 欧塞拉治疗有限公司 制备l-鸟氨酸苯基乙酸盐的方法
EP3685841A1 (en) 2014-11-24 2020-07-29 Ucl Business Ltd Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
EP3337473A4 (en) 2015-08-18 2019-04-17 Ocera Therapeutics, Inc. TREATMENT AND PREVENTION OF MUSCLE WOUND BY L-ORNITHIN IN COMBINATION WITH AT LEAST ONE PHENYL ACETATE AND PHENYL BUTYRATE
WO2017114686A1 (en) * 2015-12-30 2017-07-06 Nestec S.A. Method for determining fat free body mass
US10624869B2 (en) * 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
CA3063134A1 (en) 2017-05-11 2018-11-15 Ocera Therapeutics, Inc. Processes of making l-ornithine phenylacetate
AU2018282735A1 (en) * 2017-06-12 2020-02-06 Stanislaw R. Burzynski Methods for the treatment of leptomeningeal disease
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472B (zh) * 2022-12-14 2024-07-26 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4470970A (en) 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5254587A (en) 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5244922A (en) * 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
US6013278A (en) 1996-05-14 2000-01-11 Burzynski Research Institute Liposomal antineoplaston therapies with markedly improved antineoplastic activity

Also Published As

Publication number Publication date
AU759278B2 (en) 2003-04-10
CA2336945C (en) 2008-11-18
DK1098643T3 (da) 2004-05-24
IL140848A (en) 2005-05-17
KR100417101B1 (ko) 2004-02-05
CN1319010A (zh) 2001-10-24
KR100417100B1 (ko) 2004-02-05
DE69914084T2 (de) 2004-10-28
HK1037142A1 (en) 2002-02-01
US6258849B1 (en) 2001-07-10
KR20030027087A (ko) 2003-04-03
ES2214866T3 (es) 2004-09-16
AU4854299A (en) 2000-02-14
PT1098643E (pt) 2004-05-31
KR100414587B1 (ko) 2004-01-13
JP2011051993A (ja) 2011-03-17
WO2000004894A3 (en) 2000-04-27
ATE257378T1 (de) 2004-01-15
JP2002521329A (ja) 2002-07-16
EP1098643B1 (en) 2004-01-07
WO2000004894A2 (en) 2000-02-03
US6943192B2 (en) 2005-09-13
EP1098643A2 (en) 2001-05-16
CA2336945A1 (en) 2000-02-03
PL213698B1 (pl) 2013-04-30
KR100399658B1 (ko) 2003-09-29
KR20010071025A (ko) 2001-07-28
IL140848A0 (en) 2002-02-10
BR9912356A (pt) 2001-04-17
CN100400039C (zh) 2008-07-09
DE69914084D1 (de) 2004-02-12
CN1605334A (zh) 2005-04-13
US20010044466A1 (en) 2001-11-22
EA200100168A1 (ru) 2001-08-27
CN1191064C (zh) 2005-03-02
ZA200100622B (en) 2002-06-26
CN1660061A (zh) 2005-08-31
PL345959A1 (en) 2002-01-14
NZ509244A (en) 2004-02-27
KR20030027089A (ko) 2003-04-03
EA004179B1 (ru) 2004-02-26
KR20030027088A (ko) 2003-04-03

Similar Documents

Publication Publication Date Title
ID28160A (id) Sistem pengobatan untuk pemberian fenilasetilglutamina, fenilasetilisoglutamina dan/atau fenilasetat.
IT1255390B (it) Prodotti farmaceutici per curare malattie tumorali e procedimento per la loro preparazione
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
DK0913156T3 (da) Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
ATE319447T1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
DK1091729T3 (da) Mikropartikelformulering til inhalation
ATE241365T1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
DE69930739D1 (de) Transdermale verwendung von sekretin zur behandlung von autismus
YU54499A (sh) Farmaceutski preparat za primenu na mukozu
ATE125706T1 (de) Diphosphonate enthaltende pharmazeutische zusammensetzungen zur behandlung von arthrosis.
DE58901002D1 (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken.
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
TR200002078T2 (tr) Sentetik polisakkaridler, hazırlanmaları için proses ve bunları içeren farmasötik kompozisyonlar.
BR9708388A (pt) Solução aquosa de hemoglobina polimerizada piridoxilada e processo de sua preparação.
KR960702313A (ko) 티아조푸린 및 리바비린을 사용하는 종양질환의 치료방법 (method for the treatment of neoplastic disease utilizing tlazofurin and ribavirin)
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
ATE254469T1 (de) Verfahren zur verminderung der renalen aufnahme von antikörperfragmenten
JPS56147704A (en) Dermatological composition
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
RO102780B1 (ro) Metoda de anestezie generala
JPS5524150A (en) Anti-malignant-tumor agent
UA30393A (ru) Способ лечения коронарного атеросклероза
UA23301A (ru) Способ приготовления эмбехина для иньекций